Species isoforms of histamine H 2 -, H 3 -, and H 4 -receptors differ in their pharmacological properties. The study aim was to dissect differences between the human H 1 R (hH 1 R) and guinea pig H 1 R (ghH 1 R). We coexpressed hH 1 R and gpH 1 R with regulators of G-protein signaling in Sf9 insect cells and analyzed the GTPase activity of G q -proteins. Small H 1 R agonists showed similar effects at hH 1 R and gpH 1 R, whereas bulkier 2-phenylhistamines and histaprodifens were up to ϳ10-fold more potent at gpH 1 R than at hH 1 R. Most 2-phenylhistamines and histaprodifens were more efficacious at gpH 1 R than at hH 1 R. Several first-generation H 1 R antagonists were ϳ2-fold, and arpromidine-type H 1 R antagonists up to ϳ10-fold more potent at gpH 1 R than at hH 1 R. [ The Phe-1533 Leu-153/Ile-4333 Val-433 double mutant expressed excellently but only partially changed the pharmacological properties of hH 1 R. Small H 1 R agonists and 2-phenylhistamines interacted differentially with human and guinea pig H 2 R in terms of potency and efficacy, respectively. Our data show the following: 1) there are differences in agonist-and antagonistpharmacology of hH 1 R and gpH 1 R encompassing diverse classes of bulky ligands. These differences may be explained by higher conformational flexibility of gpH 1 R relative to hH 1 R; 2) Phe-153 and Ile-433 are critical for proper folding and expression of hH 1 R; and 3) H 2 R species isoforms distinguish between H 1 R agonists.
H]mepyramine affinity, and functional inactivity. The Phe-1533 Leu-153/Ile-4333 Val-433 double mutant expressed excellently but only partially changed the pharmacological properties of hH 1 R. Small H 1 R agonists and 2-phenylhistamines interacted differentially with human and guinea pig H 2 R in terms of potency and efficacy, respectively. Our data show the following: 1) there are differences in agonist-and antagonistpharmacology of hH 1 R and gpH 1 R encompassing diverse classes of bulky ligands. These differences may be explained by higher conformational flexibility of gpH 1 R relative to hH 1 R; 2) Phe-153 and Ile-433 are critical for proper folding and expression of hH 1 R; and 3) H 2 R species isoforms distinguish between H 1 R agonists.
Histamine serves as a neurotransmitter and autacoid and acts through specific H x Rs designated as H 1 R, H 2 R, H 3 R, and H 4 R, respectively (Hill et al., 1997; Hough, 2001) . The H 1 R couples to G q -proteins. Numerous H 1 R agonists and antagonists are known. H 1 R agonists are divided into three classes ( Fig. 1 ): 1) small agonists (2-4) derived from histamine (1), 2) histamine derivatives with bulkier aromatic substituents at position 2 of the imidazole ring (5-18), and 3) histaprodifens, e.g., compounds 19 to 23 Zingel et al., 1995; Elz et al., 2000) . H 1 R agonists are important experimental tools to analyze H 1 R function in cellular and organ systems (Zingel et al., 1995; Hill et al., 1997) . H 1 R antagonists are commonly divided into sedating (first-generation, 24-32) and nonsedating (second-generation, 41-45) antagonists (Fig. 2) . Today, especially the second-generation H 1 R antagonists are of great importance for the treatment of allergic diseases (Hill et al., 1997) . Guanidines 33, 34, and 36 to 39 derived from arpromidine (35) are dual H 2 R agonists/ H 1 R antagonists (Buschauer, 1989) .
The availability of H x R cDNAs allowed for the comparison of the pharmacological properties of H x R species isoforms in recombinant systems under identical experimental conditions. Such expression studies uncovered species differences in the pharmacological properties of hH 2 R and gpH 2 R (Kelley et al., 2001) , rat and human H 3 R (Ligneau et al., 2000; Lovenberg et al., 2000) , and H 4 R from mouse, rat, guinea pig, and humans (Liu et al., 2001 ). Species differences in the pharmacological properties of H x Rs provided opportunities to analyze the molecular basis of ligand/GPCR interactions (Ligneau et al., 2000; Kelley et al., 2001) . From the standpoint of drug design, the pharmacological properties of hH x Rs are important because in the H x R field essentially all the structures generated so far were derived from animal models, mostly from rat and guinea pig (Zingel et al., 1995; Hill et al., 1997) .
The species differences in pharmacological properties of H 2 R, H 3 R, and H 4 R raise the question whether this is a general characteristic of H x Rs. In fact, the K d values of [ 3 H]mepyramine for H 1 Rs from various species differ by ϳ2 to 6-fold (Chang et al., 1979) . Moreover, histaprodifens exhibit different potencies and efficacies in the guinea pig ileum and rat aorta (Elz et al., 2000) . Furthermore, 2-(3-chlorophenyl)histamine (12) is a potent H 1 R agonist in the guinea pig ileum but failed to exhibit agonistic activity in H 1 R-expressing dibutyryl cAMP-differentiated human HL-60 leukemia cells (Seifert et al., 1994) . A snake plot of hH 1 R depicts the relative positions and topology of amino acid residues in the TM domains, putative agonist and antagonist binding sites, and differences with respect to the gpH 1 R (Fig. 3 ). Mutagenesis data (Leurs et al., , 1995 Ohta et al., 1994; Nonaka et al., 1998) and modeling approaches (Elz et al., 2000) indicated that histamine and histaprodifens interact with amino acid residues in TMs III, IV, V, and VII. Considering the alignment of H 1 Rs with bovine rhodopsin (Palczewski et al., 2000) and results of the substituted-cysteine accessibility method with the dopamine D 2 -receptor (Ballesteros et al., 2001) , there are no amino acid differences in the ligand binding pocket of gpH 1 R and hH 1 R. The two lipid-directed residues, Phe-153 in TM IV of hH 1 R versus Leu in gpH 1 R and Ile-433 in TM VI of hH 1 R versus Val in gpH 1 R, represent the only differences near the binding site. Although these amino acid exchanges are conservative, the amino acids in hH 1 R are bulkier than those in gpH 1 R, and such differences could have an impact on the ligandbinding pocket.
The aim of the present study was to compare recombinant hH 1 R and gpH 1 R expressed in Sf9 insect cells under identical experimental conditions. We also examined the roles of Phe-153 and Ile-433 in hH 1 R function. As read-out, we focused on the determination of the GTPase activity of insect cell G qproteins in the presence of the RGS proteins RGS4 and GAIP. This coexpression system provides a sensitive model for studying H 1 R at the G-protein level (Houston et al., 2002) . The GTPase assay is a steady-state method and eliminates the impact of effector availability/compartmentation and pharmacokinetic barriers on the properties of agonists (Buschauer, 1989; Ostrom et al., 2000) . Moreover, we conducted [ 3 H]mepyramine binding studies and analyzed the effects of H 1 R agonists on recombinant H 2 R-G s␣ fusion proteins, recently verified as sensitive systems for the analysis of H 2 Rs (Kelley et al., 2001 ).
Materials and Methods
Materials. Construction of the cDNAs for hH 1 R-F153L, hH 1 R-I433V, and hH 1 R-F153L/I433V was performed by overlap-extension polymerase chain reaction following recently described procedures Fig. 1 . Structures of H 1 R agonists. 1, histamine; 2 to 4, small histamine-derived agonists; 5 to 17, 2-phenylhistamine derivatives; 18, thioether compound related to 5 to 17; 18 to 23, histaprodifens. For agonist names, see Table 2 .
Differences between Human and Guinea Pig H 1 -Receptor 1105 at ASPET Journals on July 11, 2017 jpet.aspetjournals.org (Houston et al., 2002) . Dimethindene enantiomers were a kind gift of Dr. G. Lambrecht (Department of Pharmacology, University of Frankfurt/Main, Germany). Ketotifen was a gift from Novartis (Basel, Switzerland), azelastine a gift from Asta Medica (Frankfurt/ Main, Germany), fexofenadine a gift from Janssen-Cilag (Neuss, Germany), and terfenadine a gift from Aventis (Frankfurt/Main, Germany). Guanidines 33 to 38 were synthesized as described (Buschauer, 1989) . Guanidine 39 was prepared by analogy to the procedures described for guanidines 33 to 38. 2-Methylhistamine (2) and 2-(2-thiazolyl)ethanamine (3) were synthesized using standard procedures. Compounds 5 to 18 were prepared according to published procedures (Zingel et al., 1990; Leschke et al., 1995) . Compounds 22, 23, and 40 were available by synthetic pathways reported for the synthesis of 19 to 21 (Elz et al., 2000) . Structures of synthesized compounds were confirmed by elemental analysis (C, H, and N), 1 H NMR spectroscopy, and mass spectrometry. The purity of the compounds was Ͼ98% as determined by high-performance liquid chromatography or capillary electrophoresis. Tunicamycin, histamine, betahistine, promazine, chlorpromazine, mianserin, cyproheptadine, diphenhydramine, mepyramine, triprolidine, and (ϩ)-chlorpheniramine were from Sigma-Aldrich (St. Louis, MO). Sources of other materials are described elsewhere (Kelley et al., 2001; Houston et al., 2002) .
Cell Culture and Membrane Preparation. Recombinant baculoviruses encoding hH 1 R-F153L, hH 1 R-I433V, and hH 1 R-F153L/ I433V were generated in Sf9 cells using the BaculoGOLD transfection kit (BD Pharmingen, San Diego, CA), according to the manufacturer's instructions. Infection and culture of Sf9 cells and membrane preparation were performed as described (Kelley et al., 2001; Houston et al., 2002) . In some cultures, we added tunicamycin (10 g/ml) to cultures to inhibit N-glycosylation of H 1 Rs mepyramine by filtration through GF/C filters, followed by three washes with 2 ml of binding buffer (4°C). Filter-bound radioactivity was determined by liquid scintillation counting.
Steady-State GTPase Activity Assay. Membranes expressing various H 1 R constructs plus RGS proteins or H 2 R-G s␣ fusion proteins were thawed, sedimented, and resuspended in 10 mM Tris/HCl, pH 7.4. Assay tubes contained Sf9 membranes (10 g of protein/tube), 1.0 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 g of creatine kinase, and 0.2% (w/v) bovine serum albumin in 50 mM Tris/ HCl, pH 7.4, and H x R ligands at various concentrations. Reaction mixtures (80 l) were incubated for 3 min at 25°C before the addition of 20 l of [␥- 32 P]GTP (0.2-0.5 Ci/tube). Reactions were conducted for 20 min at 25°C. Reactions were terminated by the addition of 900 l of slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH 2 PO 4 , pH 2.0. Charcoal-quenched reaction mixtures were centrifuged for 15 min at room temperature at 15,000g. Seven hundred microliters of the supernatant fluid of reaction mixtures were removed, and 32 P i was determined by liquid scintillation counting. SDS-PAGE and Immunoblot Analysis. Membrane proteins were separated on SDS polyacrylamide gels containing 10% (w/v) acrylamide. Proteins were then transferred onto Immobilon-P transfer membranes (Millipore, Bedford, MA) . Membranes were reacted with M1 antibody (1:1000). Immunoreactive bands were visualized by sheep anti-mouse IgG (1:1000) coupled to peroxidase, using odianisidine and H 2 O 2 as substrates. Expression of RGS proteins was verified by immunoblot analysis with specific anti-RGS4 IgG and anti-GAIP IgG, as described (Houston et al., 2002) .
Miscellaneous. Protein concentrations were determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). All analyses of experimental data were performed with the Prism 3.02 software (GraphPad-Prism, San Diego, CA). K i and K B values were calculated according to Cheng and Prusoff (1973) . Statistical comparisons were performed with Student's t test.
Results
Immunological Detection of H 1 R Constructs. The H 1 R constructs analyzed in this study were all N-terminally tagged with the FLAG epitope, allowing immunological detection with the M1 monoclonal antibody (Houston et al., 2002) . The predicted molecular mass of nonglycosylated hH 1 R and gpH 1 R is ϳ56 kDa Traiffort et al., 1994) . The FLAG epitope-tagged hH 1 R expressed in Sf9 membranes migrated as diffuse ϳ75-kDa doublet in SDS-PAGE (Figs. 4, A and B) . Treatment of Sf9 cells with the inhibitor of N-glycosylation, tunicamycin ), shifted the majority of the protein toward 70 kDa and rendered the lower band crisper. Migration of FLAG epitope-tagged gpH 1 R in SDS-PAGE differed considerably from the migration of hH 1 R. In membranes expressing gpH 1 R, faint and diffuse bands in the ϳ36-and ϳ50-kDa regions were detected, and tunicamycin treatment had little effect on migration of gpH 1 R in SDS-PAGE (Fig. 4A) . Additionally, we detected intense and crisp bands of ϳ16 and ϳ30 kDa. Both hH 1 R-F153L and hH 1 R-I433V showed a broad ladder of diffuse bands ranging from ϳ30 to 80 kDa, and Fig. 3 . Snake plot of hH 1 R showing the relative positions and topology of amino acid residues in the TM domains, putative agonist and antagonist binding sites, and differences with respect to the gpH 1 R. Figure 3 considers results of the substituted cysteine accessibility method by which the dopamine D 2 -receptor binding site was mapped (Ballesteros et al., 2001) . Red circles, amino acids predicted to face the interior of the TM helix bundle based on corresponding positions in bovine rhodopsin (Palczewski et al., 2000) . Blue circles, amino acids predicted to face lipid. Red letters, the corresponding amino acids in the dopamine D 2 -receptor are water-accessible and protected by ligand binding in substituted-cysteine accessibility experiments (Ballesteros et al., 2001) . Magenta letters, amino acids that are water accessible but not protected by ligand binding in substituted cysteine accessibility experiments. Red shading, histamine binding site residues according to site-directed mutagenesis data (Leurs et al., , 1995 Ohta et al., 1994; Nonaka et al., 1998) . Green shading, amino acid of the H 1 R antagonist binding site based on mutagenesis studies (Ohta et al., 1994; Nonaka et al., 1998; Wieland et al., 1999) . Yellow shading, amino acids that are essential for both histamine and H 1 R antagonist binding (Wieland et al., 1999) . Orange shading, additional amino acid residues of the histaprodifen binding site based on molecular modeling approaches (Elz et al., 2000) . Note that Lys-191 does not interact with histaprodifens. Blue shading, amino acids targeted by site-directed mutagenesis in the present article. Gray shading, other amino acid residues different between hH 1 R and gpH 1 R. Brown line, conserved disulfide bridge between Cys-100 and Cys-180. Numbers designate the first and last amino acids, respectively, of each TM domain.
Differences between Human and Guinea Pig H 1 -Receptor 1107 at ASPET Journals on July 11, 2017 jpet.aspetjournals.org there was a more intense doublet at 28 to 29 kDa (Fig. 4B) . The hH 1 R-F153L/I433V double mutant showed the predicted migration in SDS-PAGE, i.e., this mutant migrated as a ϳ56 kDa band. Table 1 ). The B max values of hH 1 R and gpH 1 R expression in Sf9 membranes were similar to the expression levels reported for the ␤ 2 -adrenoceptor (Seifert et al., 1998) . Compared with hH 1 R, the [ 3 H]mepyramine-affinities of hH 1 R-F153L and hH 1 R-I433V were reduced by ϳ8-to 12-fold, and the B max values were reduced by ϳ5-to 6-fold. The double mutation restored [
3 H]mepyramine-affinity of hH 1 R and efficient expression.
Potencies and Efficacies of H 1 R and H 2 R Agonists at H 1 R Constructs in the GTPase Assay. We studied three classes of H 1 R agonists in the GTPase assay (Fig. 1) . As a control we also studied the H 2 R agonists amthamine (46) and dimaprit (47) (Hill et al., 1997) . Table 2 and Fig. 5 summarize the data for hH 1 R and gpH 1 R coexpressed with RGS4 and GAIP since no significant differences were observed between the two RGS proteins (data not shown). Only histamine and the small histamine derivatives 2 and 3 were full hH 1 R agonists, whereas all other modifications resulted in reductions of efficacy. Additionally, compounds 2 and 3 were less potent hH 1 R agonists than histamine. We identified only two agonists that were more potent at hH 1 R than histamine, i.e., the histaprodifens 19 and 20. The moderate increase in potency (1.8 -2.7-fold) was accompanied by a significant decrease in efficacy, however. The introduction of a phenyl group (6) or particularly a benzyl group (5) at the position 2 of the imidazole ring substantially reduced agonist potency. Introduction of a halogen in the meta-position of the phenyl ring partially restored agonist potency in the order F Ͻ Cl Ͻ Br ϳ I (compare 6, 9, 12, 14, and 15). Other hydrogendonating meta-substituents (Oe and CF 3 ) were also favorable (16 and 17), whereas a methyl group (7) and halogen substitutions in the ortho-or para-position of the phenyl ring (8 and 13) further reduced agonist potency. At hH 1 R, histaprodifens 21 to 23 were less potent than histamine. The H 2 R agonists 46 and 47 were essentially devoid of agonistic activity at the hH 1 R (Table 2) .
We did not observe significant differences in potency and efficacy of the small H 1 R agonists 1 to 4 between hH 1 R and gpH 1 R (Table 2 ). This similarity between the H 1 R isoforms is reflected by a linear correlation of the pEC 50 values of the small agonists at hH 1 R and gpH 1 R that is close to the theoretical correlation describing identity of H 1 R species isoforms (Fig. 5A ). When the effects of 2-phenylhistamines and histaprodifens were analyzed, however, significant differences between hH 1 R and gpH 1 R emerged. All compounds of these two classes were significantly more potent (3.2-to 9.9-fold) at gpH 1 R than at hH 1 R. The different interaction of 2-phenylhistamines and histaprodifens with hH 1 R and gpH 1 R is reflected by a linear correlation of the potencies of each series that is shifted toward the left relative to the theoretical correlation describing pharmacological identity of the GPCR species isoforms (Figs. 5, B and C). These linear correlations also show that the overall structure/activity relationships of those compounds are similar at both H 1 R species isoforms. In addition to the higher potency, most 2-phenylhistamines (6, 8-12, 14-17) and 3 of 5 histaprodifens (20, 21, and 23) were significantly more efficacious at gpH 1 R than at hH 1 R. Finally, the small H 2 R agonist dimaprit (47) showed only minimal agonistic effects at gpH 1 R, but another small agonist, amthamine (46), was a weak partial gpH 1 R agonist with significantly higher efficacy at gpH 1 R than at hH 1 R.
We failed to detect GTPase stimulation by histamine and compounds 3 and 12 in Sf9 membranes expressing hH 1 R-F153L and hH 1 R-I433V plus RGS proteins (data not shown). In contrast, histamine and compound 3 stimulated GTP hydrolysis in membranes expressing hH 1 R-F153L/I433V as potently and efficiently as in membranes expressing hH 1 R or gpH 1 R. 2-Substituted histamines and histaprodifens tended to be more potent and efficacious at hH 1 R-F153L/I433V than Table 1 . x R ligands at concentrations from 1 nM to 1 mM as appropriate to generate saturated concentration/response curves. Data were analyzed by nonlinear regression and were best fit to sigmoid concentration/response curves. Typical basal GTPase activities ranged between 1.5 to 2.5 pmol/mg/min, and the maximum stimulatory effect of histamine (10 M) amounted to 125 to 175% above basal. The efficacy (E max ) of histamine was determined by nonlinear regression and was set 1. (Rel. Pot.) of histamine was set 100, and the potencies of other agonists were referred to this value. Finally, we calculated the ratio of the relative potency of H 1 R agonists at the native gpH 1 R expressed in the ileum and recombinant gpH 1 R expressed in Sf9 membranes (Pot. Rat. rec/il). The relative potencies of compounds 2 to 23 in the guinea pig ileum were calculated from isotonically recorded cumulative concentration/response curves on whole segments of ileum (preload 0.5 g) in the continuous presence of atropine (100 nM) as described (Elz et al., 2000) . Cpd. jpet.aspetjournals.org at hH 1 R, but only the potency and efficacy of compound 12 were significantly increased. Constitutive Activity of H 1 Rs. hH 1 R is constitutively active, and many first-and second-generation H 1 R antagonists possess inverse agonistic activity (Bakker et al., 2001; Weiner et al., 2001) . The extent of constitutive activity of hH 1 R is dependent on the specific expression system, however. All first-generation H 1 R antagonists (24-32), secondgeneration H 1 R antagonists (41-45), and guanidines (33-39) examined exhibited only small inverse agonistic activity at hH 1 R expressed in Sf9 membranes, i.e., the inhibitory effects of compounds amounted to ϳ5 to 15% of the stimulatory effect of histamine (data not shown). There were no significant differences in the inverse agonist effects of H 1 R antagonists at hH 1 R and gpH 1 R. These data indicate that the constitutive activity of the two GPCR isoforms is similar.
Potencies of H 1 R Antagonists at H 1 R Constructs in the GTPase Assay. In agreement with the [ 3 H]mepyramine binding studies (Table 1) , mepyramine (30) was about 2-fold less potent at inhibiting histamine-stimulated GTP hydrolysis in membranes expressing hH 1 R than in membranes expressing gpH 1 R (Table 3) . A similar difference in potency was (Pfaff et al., 1995) . Among the second-generation H 1 R antagonists 41 to 45, no significant differences in potency between hH 1 R and gpH 1 R emerged. Arpromidine (35) and arpromidine-derived guanidines (33, 34, and 36-38) are not only very potent H 2 R agonists but also moderately potent H 1 R antagonists (Buschauer, 1989) . The H 1 R-antagonistic properties of guanidines are explained by the structural similarity of compounds 33 to 38 and 30 to 32 (Fig. 2) . Guanidines 33 to 38 inhibited histamine-stimulated GTP hydrolysis in Sf9 membranes expressing gpH 1 R, with K B values of ϳ50 to 150 nM (Table 3) . Guanidines 33 to 38 were all significantly more potent antagonists at gpH 1 R than at hH 1 R and showed greater gpH 1 R/hH 1 R selectivity than compounds 30 to 32. The difference in potency was most pronounced (ϳ9-fold) for compound 36 that is distinguished from the other guanidines by a para-Cl in the phenyl moiety (Fig. 2) . In contrast, guanidine 39 that possesses a trichlorinated phenyl ring and a thiazole instead of a pyridyl ring (Fig. 2) did not discriminate between hH 1 R and gpH 1 R. Modifications of the substituents in guanidines 33-39 had a considerably larger impact on antagonist potency at gpH 1 R (ϳ7-fold) than at hH 1 R (ϳ2-fold).
In the 2-phenylhistamine derivative 40, the free amino group of histamine was integrated into a piperidine ring (Fig.  2) . This modification is predicted to interfere with the binding of the basic nitrogen to Asp-107 (hH 1 R) (Ohta et al., 1994) . In fact, compound 40 exhibited 6.5-to 8-fold reduced apparent affinity compared with its parent compound (17) (Fig. 1) at hH 1 R and gpH 1 R (Tables 2 and 3 ). Moreover, introduction of the piperidine ring into 17 conferred antagonistic properties to compound 40 (Table 3) . This was also confirmed in the guinea pig ileum assay (K B of compound 40, 400 nM). Compound 40 was a severalfold more potent antagonist at gpH 1 R than at hH 1 R.
In agreement with the binding data (Table 1) , mepyramine (30) was similarly potent at inhibiting histamine-stimulated GTP hydrolysis in Sf9 membranes expressing hH 1 R and hH 1 R-F153L/I433V (Table 3 ). The double mutation exhibited inconsistent effects on the potencies of guanidines 33 and 35 to 38 as well as of the 2-phenylhistamine derivative 40. Specifically, the F153L/I433V mutation increased the potency of 36 1.5-fold, had no effect on the potency of 35, and 37 and decreased the potency of compounds 33, 38, and 40 by up to 2-fold.
Affinities of H 1 R Agonists and Antagonists at H 1 R Constructs in the [
3 H]Mepyramine Binding Assay. Histamine and 2-(3-chlorophenyl)histamine (12) inhibited [ 3 H]mepyramine binding in Sf9 membranes expressing hH 1 R or gpH 1 R plus RGS proteins according to a monophasic function that was not shifted to the right by guanosine 5Ј-O-(3-thiotriphosphate) (10 M) (data not shown). Thus, we could not detect high-affinity agonist binding. These data were expected since there is a paucity of endogenous G-proteins relative to the expressed mammalian GPCRs in Sf9 membranes (Seifert et al., 1998; Houston et al., 2002 1, 3, 12, 14, 15, 19 , and 20 at hH 1 R and gpH 1 R were all higher than the corresponding EC 50 values in the GTPase assay (Tables 2 and 4) . The K i value of histamine at hH 1 R was 2.3-fold lower than the K i value of histamine at gpH 1 R. Since the amino acids in the histaminebinding H 1 R domains are identical in both isoforms (Fig. 3) , this difference could point to a better fit of histamine into the G q -uncoupled hH 1 R compared with G q -uncoupled gpH 1 R.
To account for the difference in histamine affinity of H 1 R species isoforms, we focused on the comparison of the relative affinities of synthetic agonists at hH 1 R and gpH 1 R. The relative affinity of the small agonist 3 was similar at hH 1 R and gpH 1 R, whereas the relative affinities of the 2-phenylhistamines 12, 14, and 15 and of the histaprodifens 19 and 20 were ϳ3-to 7-fold higher at gpH 1 R than at hH 1 R. These differences fit to the differences in relative agonist potencies observed in the GTPase assay (Table 2 ). In agreement with the GTPase studies (Table 3) , the H 1 R antagonists triprolidine (31), arpromidine (35), and BU-E 47 (36) also all exhibited significantly higher binding affinities at gpH 1 R than at hH 1 R (Table 4) .
We also studied the impact of the F153L/I433V mutation in hH 1 R on ligand-affinities. The double mutation significantly decreased the affinity of hH 1 R for histamine and 2-(2-thiazolyl)ethanamine (3) (Table 4). Similar data were obtained for the comparison of hH 1 R and gpH 1 R. Additionally, in membranes expressing hH 1 R-F153L/I433V, the relative affinities of 2-phenylhistamines and histaprodifens were increased relative to hH 1 R, but with the exception of methylhistaprodifen (19), those changes were not as marked as for the comparison of hH 1 R and gpH 1 R. The affinities of triprolidine (31), arpromidine (35), and guanidine 36 at hH 1 R and hH 1 R-F153L/I433V were similar.
Potencies and Efficacies of H 1 R Agonists at hH 2 R and gpH 2 R in the GTPase Assay. The question arose whether H 1 R agonists, originally designed for gpH 1 R in comparison to gpH 2 R, interact differentially with the corresponding human H x Rs. To address this question, we analyzed the effects of H 1 R agonists on GTP hydrolysis in Sf9 membranes expressing H 2 R-G s␣S fusion proteins. We examined all H 1 R agonists shown in Fig. 1 and listed in Table 2 (1-23) but included only those compounds into Table 5 that actually exhibited agonistic activity at H 2 Rs. To account for the fact that the potency of histamine in the GTPase assay in membranes expressing H 1 Rs and H 2 Rs differs by almost 10-fold (Tables 2 and 5 ) (Kelley et al., 2001) , we focused on the comparison of relative potencies of H 1 R agonists.
2-Methylhistamine (2) and 2-(2-thiazolyl)ethanamine (3) were strong partial agonists at gpH 2 R with moderate (2.3-to 5-fold) gpH 1 R/gpH 2 R selectivity. The introduction of a (substituted) phenyl group at position 2 of the imidazole ring greatly reduced the efficacy of H 1 R agonists at gpH 2 R and further increased gpH 1 R/gpH 2 R selectivity in terms of potency. Several 2-phenylhistamines (11, 13-15, 17, and 18) and histaprodifens 19 to 21, and 23 were devoid of agonistic activity at gpH 2 R-G s␣S .
The analysis of histaprodifens at gpH 2 R-G s␣S revealed the H͔mepyramine and unlabeled H 1 R ligands at concentrations of 0.1 nM to 10 mM as appropriate to generate saturated competition curves. Data were analyzed by nonlinear regression and were best fit to one-site (monophasic) competition curves.
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Data shown are the means Ϯ S.D. of three to five experiments performed in duplicates each. The relative affinity of histamine (Rel. Aff.) was set 100, and the affinities of other agonists were referred to this value. We also calculated the ratio of the 1 R ligands at concentrations from 10 nM to 1 mM as appropriate to generate saturated concentration/response curves. Data were analyzed by nonlinear regression and were best fit to sigmoid concentration/response curves. Typical basal GTPase activities ranged between 1.0 to 2.0 pmol/mg/min, and the maximum stimulatory effect of histamine (100 M) amounted to 200 to 300% above basal. The efficacy (E max ) of histamine was determined by nonlinear regression and was set 1.00 The E max values of other H 1 R agonists were referred to this value. Data shown are the means Ϯ S.D. of three to 4 experiments performed in duplicates each. The relative potency (Rel. Pot.) of histamine was set 100, and the potencies of other agonists were referred to this value. We also calculated the ratio of the relative potencies of H 1 R agonists at hH 1 R (taken from Cpd., compound; -, not applicable because stimulatory effects of agonists were too small.
* P Ͻ 0.05 for comparison of hH 2 R versus gpH 2 R. existence of a strong partial H 1 R agonist/moderate partial H 2 R agonist, N ␣ -(imidazolylethyl)histaprodifen (22) (Tables  2 and 5 ). The H 2 -agonistic activity of this compound can be explained by its structural similarity with guanidines 33 to 38 (Figs. 1 and 2) that are potent H 2 R agonists (Buschauer, 1989; Kelley et al., 2001) .
Although histamine was similarly potent at stimulating GTP hydrolysis in Sf9 membranes expressing hH 2 R-G s␣S and gpH 2 R-G s␣S , 2-methylhistamine (2) and 2-(2-thiazolyl)ethanamine (3) were significantly less potent agonists at hH 2 R-G s␣S than at gpH 2 R-G s␣S and showed greater hH 1 R/hH 2 R selectivity (8.4-to 11.2-fold) than gpH 1 R/gpH 2 R selectivity (2.3-to 5-fold). If one considers the absolute EC 50 values of compound 3 for GTPase activation in membranes expressing hH 1 R and hH 2 R-G s␣S , the selectivity for hH 1 R becomes even more striking (75-versus 23-fold for gpH x Rs). In contrast to compound 3, another small H 1 R agonist, betahistine (4), exhibited considerably higher gpH 1 R/gpH 2 R selectivity (10-fold) than hH 1 R/hH 2 R selectivity (3.5-fold) . Similar to the data obtained for gpH 2 R, several 2-phenylhistamines (11, 13-15, 17, and 18) and histaprodifens (19-21 and 23) were devoid of agonistic activity at hH 2 R-G s␣S . As was the case for gpH x Rs, N ␣ -(imidazolylethyl)-histaprodifen (22) was a strong partial hH 1 R agonist/moderate partial hH 2 R agonist. There were no significant differences in the interaction of histaprodifens at hH 2 R-G s␣S and gpH 2 R-G s␣S . Finally, the efficacies of the 2-phenylhistamines 6 to 9 were significantly lower at hH 2 R-G s␣S than at gpH 2 R-G s␣S (Table 5) and therefore in the same order as observed for hH 1 R and gpH 1 R (Table 2) .
Discussion
Pharmacological Differences between hH 1 R and gpH 1 R. hH 1 R is an important drug target for treatment of allergic diseases (second-generation H 1 R antagonists) and sedation (first-generation H 1 R antagonists) (Hill et al., 1997) . Preliminary data indicate that pharmacological differences between H 1 R species isoforms exist (Chang et al., 1979; Seifert et al., 1994; Elz et al., 2000) , but a systematic analysis of this topic has not yet been conducted. Therefore, we studied recombinant hH 1 R and gpH 1 R with 23 H 1 R agonists (1-23) (Fig. 1) , 22 H 1 R antagonists (24-45) (Fig. 2) , and two H 2 R agonists (46 and 47) under identical experimental conditions, using the GTPase assay ( There were no significant differences between hH 1 R and gpH 1 R with respect to the potencies and efficacies of small agonists (1-4) in the GTPase assay ( Fig. 5; Table 2 ). With respect to bulkier ligands, however, we found significant differences between hH 1 R and gpH 1 R. Specifically, H 1 R agonists of the 2-phenylhistamine class (6-17) and histaprodifen class (19-23) were generally more potent and efficacious in the GTPase assay in membranes expressing gpH 1 R than in membranes expressing hH 1 R ( Fig. 5; Table 2 ). Additionally, in the binding assay, 2-phenylhistamines and histaprodifens exhibited higher relative affinities for gpH 1 R than for hH 1 R (Table 4 ). The differential interaction of 2-phenylhistamine derivatives with gpH 1 R and hH 1 R is independent of the agonist or antagonist properties of compounds (compare 17 and 40; Tables 2 and 3 ). High constitutive GPCR activity results in high agonist potency and efficacy (Kenakin, 1996; Seifert and Wenzel-Seifert, 2002 ), but we did not find differences in constitutive activity between hH 1 R and gpH 1 R studying inverse agonists. Finally, several first-generation H 1 R antagonists (30-32) and particularly arpromidine-type H 1 R antagonists (33-38) showed higher affinities for gpH 1 R than for hH 1 R. Our data concerning the affinity of ([ 3 H])mepyramine for hH 1 R and gpH 1 R (Tables 1 and 3 ) fit very well to previously published data on H 1 R species isoforms expressed in native brain (Chang et al., 1979) . Collectively, our data suggest that the ligand-binding site of gpH 1 R exhibits a higher conformational flexibility than the ligandbinding site of hH 1 R, allowing bulky compounds like 2-phenylhistamines, histaprodifens, mepyramine-type antagonists, and guanidines to dock more efficiently into gpH 1 R than into hH 1 R.
Most of the previous H 1 R antagonist development had been conducted with guinea pig models (Hill et al., 1997) . Thus, from a therapeutic standpoint, it is fortunate that there are no or only small differences between hH 1 R and gpH 1 R with respect to commonly used first-generation H 1 R antagonists (e.g., 24-28, 30, and 32) and second-generation antagonists (41-45). Nevertheless, with regard to the design of H 1 R agonists and guanidine-type H 1 R antagonists, which are currently used only as experimental tools (Zingel et al., 1995; Hill et al., 1997) , the H 1 R species isoform is of much greater relevance.
Differences in Electrophoretic Mobility between hH 1 R and gpH 1 R. A previous study showed that H 1 R isoforms expressed in brain from various species exhibit different migration in SDS-PAGE (Ruat and Schwartz, 1989) . These data prompted us to study the electrophoretic mobility of recombinant FLAG epitope-tagged recombinant hH 1 R and gpH 1 R (Fig. 4) . In agreement with the data concerning native H 1 R species isoforms, recombinant H 1 R species isoforms showed different migration in SDS-PAGE. hH 1 R exhibited a moderately higher molecular mass (ϳ76 kDa) than predicted (ϳ56 kDa) . hH 1 R migrated as mixture of N-glycosylated and nonglycosylated protein, as assessed by the effect of the inhibitor of N-glycosylation, tunicamycin ). Recombinant gpH 1 R exhibited very different migration in SDS-PAGE than hH 1 R, i.e., we detected faint diffuse ϳ36-and ϳ50-kDa bands and intense crisp ϳ16-and ϳ30-kDa bands in Sf9 membranes expressing gpH 1 R. In contrast to the results obtained with hH 1 R, tunicamycin had no effect on migration of gpH 1 R, pointing to different types of glycosylation in the two H 1 R species isoforms. Currently, we do not know the identity of the multiple bands in Sf9 membranes expressing gpH 1 R, but atypical migration of GPCRs in SDS-PAGE has been repeatedly observed (Grü newald et al., 1996; Kelley et al., 2001; Seifert and Wenzel-Seifert, 2001 ). Because even complex supramolecular structures such as GPCR dimers are preserved in SDS-PAGE (Fukushima et al., 1997; Hebert and Bouvier, 1998; Kelley et al., 2001) , it is possible that the different electrophoretic mobilities of hH 1 R and gpH 1 R reflect different GPCR conformations. The different GPCR conformations may be associated with the specific pharmacological properties of H 1 R species isoforms.
Molecular Basis for the Pharmacological Differences between hH 1 R and gpH 1 R. Site-directed mutagenesis was successful at identifying the molecular basis for pharmacological differences between species isoforms of H 2 R and H 3 R ( jpet.aspetjournals.org to apply the same strategy to H 1 R species isoforms. The pharmacological data discussed above indicate that the ligand-binding pocket of gpH 1 R is more flexible than the binding pocket of hH 1 R. Thus, gpH 1 R may possess smaller amino acid substitutions in the ligand-binding domain than hH 1 R so that bulkier structures are accommodated more easily in gpH 1 R than in hH 1 R. In fact, the amino acid substitutions at positions 153 (TM IV) and 433 in hH 1 R (TM VI) are bulkier than the corresponding amino acid substitutions in gpH 1 R (Phe3 Leu exchange in TM IV and Ile3 Val exchange in TM VI, respectively). Nevertheless, the Phe3 Leu exchange in TM IV and the Ile3 Val exchange in TM VI only partially explain the differences in agonist-pharmacology between hH 1 R and gpH 1 R (Tables 2 and 4 ). Moreover, with respect to the differences in antagonist-pharmacology, the Phe3 Leuand Ile3 Val exchanges between hH 1 R and gpH 1 R are irrelevant (Tables 3 and 4 ). Thus, additional mutagenesis studies targeting the top portions of TM II and TM VII are required to elucidate the molecular basis for the pharmacological differences between hH 1 R and gpH 1 R (Fig. 3) .
Although our mutagenesis studies were disappointing in terms of elucidating the molecular basis for the pharmacological differences between hH 1 R and gpH 1 R, our studies revealed an unexpected role of Phe-153 and Ile-433 in H 1 R expression and folding. Specifically, Phe-1533 Leu-153-or Ile-4333 Val-433 exchange in hH 1 R (hH 1 R3gpH 1 R) resulted in poor receptor expression, low [ 3 H]mepyramine affinity, and functional inactivity (Table 1) . Moreover, the mutations grossly altered the electrophoretic mobility of hH 1 R (Fig. 4) . The double mutation rescued the single mutants in terms of function (Tables 1-4) , and it also changed electrophoretic mobility (Fig. 4) . These data suggest that the couples Phe-153/Ile-433 or Leu-153/Val-433 are required for a functionally active H 1 R. Thus, even conservative amino acid substitutions in TM regions can have profound effects on antagonist affinity, expression, and folding of a GPCR.
Comparison of the Effects of H 1 R Agonists at Recombinant and Native gpH 1 R. Historically, the guinea pig ileum has been the standard system for the design of H 1 R ligands (Zingel et al., 1995; Hill et al., 1997) . Therefore, it is important to compare the intact organ data with the results regarding recombinant H 1 R. Although many highly potent H 2 R and H 3 R agonists (i.e., ligands ϳ50-to 150-fold more potent than histamine) were developed (Hill et al., 1997) , the design of potent H 1 R agonists has been a much more difficult task. In fact, the most potent 2-phenylhistamine, 2-(3-trifluoromethylphenyl)histamine (17), is only 1.3-fold more potent, and methylhistaprodifen (20) just ϳ3.5-fold more potent, than histamine in the guinea pig ileum Zingel et al., 1995; Elz et al., 2000) (Table 2 ).
The expression level of H 1 R in the guinea pig ileum is much lower than in the Sf9 cell expression system (Table 1) (Hill et al., 1997) . If there had been differences in receptor reserves between the two systems, we would have expected higher agonist efficacies in the recombinant system than in the native system (Hoyer and Boddeke, 1993; Kenakin, 1996) . The opposite was the case, however (Table 2) Zingel et al., 1995; Elz et al., 2000) . Thus, we can rule out differences in receptor reserves accounting for the pharmacological differences between the two systems.
All agonists studied with the exception of 1, 3, 22, and 23 were more potent at the recombinant gpH 1 R than at the native gpH 1 R ( Table 2 ). The increase in potency at the recombinant gpH 1 R ranged from ϳ2-fold to almost 20-fold and was most pronounced for the 2-phenylhistamines 7, 11, and 13. Several explanations that are not mutually exclusive could account for the potency differences in the two systems. First, there may be substantial penetration barriers for certain agonists to reach the tunica muscularis of the ileum. Second, compounds may accumulate in certain irrelevant cells, i.e., epithelial cells, and/or, third, they may be subject to degradation. These pharmacokinetic factors are very unlikely to be of relevance when assessing the effects of ligands in membrane fragments of insect cells. Fourth, it is possible that differences in gpH 1 R glycosylation in insect cells versus native tissue contribute to the pharmacological differences in the two systems. Indeed, changes in glycosylation of H 1 R have already been shown to alter the pharmacological properties of the GPCR (Mitsuhashi and Payan, 1989) . Fifth, we studied coupling of H 1 Rs to insect cell G q -proteins (Houston et al., 2002) , and the specific type of G q -protein may have an impact on the pharmacological properties of gpH 1 R (Wenzel- Seifert and Seifert, 2000) . In contrast to the above-discussed data, the high potency of compounds 22 and 23 in the guinea pig ileum does not fit to the results obtained with recombinant gpH 1 R. Additional studies with 22, 23, and closely related new compounds must be performed to clarify this discrepancy.
Collectively, previous studies on the guinea pig ileum resulted in considerably lower potencies of most H 1 R agonists than in the recombinant system. Although the high potency of H 2 R-and H 3 R agonists has not yet been achieved for H 1 R agonists, our present study shows that gpH 1 R agonists with up to ϳ12-fold higher potency than histamine exist, provided that the GPCR is analyzed in the GTPase assay using membranes. Thus, future studies on the design of H 1 R agonists should be complemented with the recombinant system described herein.
Species Differences in Pharmacological Properties of H x Rs. H 2 R, H 3 R, and H 4 R all exhibit species differences in their pharmacological properties (Ligneau et al., 2000; Lovenberg et al., 2000; Kelley et al., 2001; Liu et al., 2001 ). Thus, we were not too surprised to uncover differences in the pharmacological properties of H 1 R species isoforms. The species differences in pharmacological properties of H x Rs extend into H x R subtype-selectivity of compounds. There are numerous efficacious H 1 R agonists of the 2-phenylhistamine and histaprodifen class with high gpH 1 R/gpH 2 R selectivity (Tables 2 and 5) Zingel et al., 1995; Elz et al., 2000) . For the analysis of hH 1 R, however, one has to consider the fact that 2-phenylhistamines and histaprodifens possess substantially lower efficacies than histamine (Table  2) . Unexpectedly, 2-(2-thiazolyl)ethanamine (3), a small agonist with full efficacy at hH 1 R, exhibited a larger hH 1 R/ hH 2 R-than gpH 1 R/gpH 2 R-selectivity (Tables 2 and 5 ). Thus, for the analysis of hH 1 R with a selective hH 1 R agonist, compound 3 may be the ligand of choice. These findings emphasize the importance to study hH x R isoforms for the development of hH x R ligands. Future studies will have to answer the question whether the species differences in pharmacological properties of H x Rs reflect species-specific adaptations to as yet unidentified endogenous and/or exogenous H x R ligands. Although H 1 Rs and H 2 Rs are structurally quite distinct from each other (only ϳ40% homology) (Traiffort et al., 1994;  1114 Seifert et al. at ASPET Journals on July 11, 2017 jpet.aspetjournals.org Downloaded from Hill et al., 1997) , there is a common aspect in the pharmacological properties of these GPCRs, i.e., the preferential interaction of bulky agonists with gpH x Rs relative to hH x Rs. Most notably, arpromidine-derived guanidines represent a class of ligands that exhibit higher affinities for gpH 1 R and gpH 2 R relative to hH x Rs (Tables 3 and 4) (Kelley et al., 2001 ). Those differences may indicate that gpH x Rs in general possess a higher conformational flexibility than hH x Rs.
